SGI
EGRX

Summit Global Investments’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Summit Global Investments’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-34,325
Closed -$907K – 501
2022
Q3 		$907K Buy
34,325
+587
+2% +$21.5K 0.08% 206
2022
Q2 		$1.5M Buy
33,738
+1,555
+5% +$71.4K 0.13% 163
2022
Q1 		$1.59M Sell
32,183
-3,536
-10% -$170K 0.12% 175
2021
Q4 		$1.82M Sell
35,719
-1,500
-4% -$77.7K 0.12% 155
2021
Q3 		$2.08M Sell
37,219
-1,100
-3% -$54.1K 0.16% 123
2021
Q2 		$1.64M Sell
38,319
-146
-0.4% -$6.03K 0.1% 159
2021
Q1 		$1.61M Buy
38,465
+7,021
+22% +$326K 0.1% 150
2020
Q4 		$1.46M Buy
31,444
+1,255
+4% +$58.7K 0.15% 125
2020
Q3 		$1.28M Buy
30,189
+2,189
+8% +$95.8K 0.13% 110
2020
Q2 		$1.34M Buy
28,000
+13,800
+97% +$689K 0.15% 97
2020
Q1 		$653K Buy
+14,200
New +$713K 0.1% 137

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Summit Global Investments's EGRX Position: Q4 2022 in Review

Summit Global Investments sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2022, closing a stake of 34,325 shares — an estimated $907K sold.

Summit Global Investments first reported a position in EGRX in Q1 2020 and held it in 11 quarters. The position peaked at $2.08M in Q3 2021. 152 funds tracked by Wall St. Rank hold EGRX as of Q4 2022.

  • Summit Global Investments reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Summit Global Investments sold 34,325 Eagle Pharmaceuticals, Inc. shares in Q4 2022, an estimated $907K.
  • Summit Global Investments first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2020 and held it in 11 quarters.
  • Summit Global Investments's Eagle Pharmaceuticals, Inc. position peaked at $2.08M in Q3 2021.
  • 152 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2022.

Based on Summit Global Investments's 13F filing for Q4 2022, filed 31 Jan 2023.